The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).
Patients assigned to the study drug were more likely to experience grade 3/4 adverse events (AEs; 45.1% vs 34.2%). The rate of serious AEs was slightly higher with apalutamide (24.8% vs 23.1%). Ten patients in the apalutamide group and 1 in the placebo group died due to AEs.
Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer [published online February 8, 2018]. New Engl J Med. doi: 10.1056/NEJMoa1715546.
... to read the full story